# Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection

> **NCT00390078** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 30 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** MVA-mBN32
- **BIOLOGICAL:** IMVAMUNE

## Key facts

- **NCT ID:** NCT00390078
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2007-12
- **Final completion:** 2009-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2009-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00390078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00390078, "Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00390078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*